Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) have received an average rating of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $25.50.
Several equities analysts have recently issued reports on MNTA shares. Stifel Nicolaus set a $39.00 price target on Momenta Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 7th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Thursday, January 3rd. Cantor Fitzgerald set a $16.00 price objective on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 7th. Finally, JPMorgan Chase & Co. downgraded Momenta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Friday, January 4th.
Get Momenta Pharmaceuticals alerts:In related news, CEO Craig A. Wheeler sold 2,601 shares of the stock in a transaction that occurred on Friday, February 8th. The stock was sold at an average price of $11.76, for a total transaction of $30,587.76. Following the completion of the transaction, the chief executive officer now directly owns 186,174 shares of the company’s stock, valued at $2,189,406.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Craig A. Wheeler sold 12,883 shares of the stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $12.92, for a total value of $166,448.36. Following the transaction, the chief executive officer now directly owns 181,800 shares of the company’s stock, valued at $2,348,856. The disclosure for this sale can be found here. Insiders have sold 21,526 shares of company stock valued at $271,578 over the last three months. Insiders own 3.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Putnam Investments LLC acquired a new stake in shares of Momenta Pharmaceuticals in the third quarter valued at approximately $6,706,000. MetLife Investment Advisors LLC lifted its position in shares of Momenta Pharmaceuticals by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 55,347 shares of the biotechnology company’s stock valued at $1,456,000 after buying an additional 19,674 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Momenta Pharmaceuticals by 7.8% in the third quarter. Legal & General Group Plc now owns 183,105 shares of the biotechnology company’s stock valued at $4,719,000 after buying an additional 13,239 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Momenta Pharmaceuticals by 3.2% in the third quarter. Bank of New York Mellon Corp now owns 894,031 shares of the biotechnology company’s stock valued at $23,513,000 after buying an additional 27,708 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Momenta Pharmaceuticals by 3.8% in the third quarter. Vanguard Group Inc. now owns 7,597,950 shares of the biotechnology company’s stock valued at $199,827,000 after buying an additional 280,177 shares during the last quarter. 76.86% of the stock is owned by hedge funds and other institutional investors.
Shares of MNTA traded up $1.12 during trading hours on Tuesday, hitting $13.68. 790,895 shares of the stock traded hands, compared to its average volume of 574,697. Momenta Pharmaceuticals has a 1-year low of $9.55 and a 1-year high of $32.20. The firm has a market capitalization of $1.35 billion, a PE ratio of -11.40 and a beta of 2.04.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Featured Story: How to Track your Portfolio in Google Finance
No comments:
Post a Comment